Objective:

To inform about the FDA's approval of Afrezza for children and adolescents with diabetes.

Key Findings:

• Afrezza offers a needle-free mealtime insulin option for pediatric patients.
• It is recognized in the American Diabetes Association Standards of Care.
• For type 1 diabetes, Afrezza must be used with basal insulin.

Interpretation:

Afrezza may help clinicians tailor insulin therapy to the daily lives of children and families.

Limitations:

• Not indicated for treatment of diabetic ketoacidosis.
• Not for use in patients with chronic lung disease or those who smoke.
• Safety and efficacy in children younger than 6 years is unknown.

Conclusion:

Afrezza expands treatment options for pediatric diabetes management.